-
What are the biomarkers related to PARP inhibitors for epithelial ovarian cancer?
Time of Update: 2021-10-20
details as follows:1 ) It is recommended that all patients with non-mucinous ovarian cancer should be clear of the mutation status of the tumor BRCA1/2 (including germline and somatic mutations) when the initial pathological examination is diagnosed .
-
Surg Neurol Int.: Case report of epidural extension of D1-D7 hemangioma on the dorsal side of the spine with congenital skin hemangioma
Time of Update: 2021-10-20
Blood vesselCase description:Case description: Case description:A 24-year-old man with multiple spinal hemangioma (MVH) with epidural extension (that is, significant spinal cord compression on D1-D3) and 6 months of progressive lower extremity paresis, and congenital D2-D7 levels Skin lesions .
-
Front Oncol: Risk factors for locally recurring breast cancer patients and the effect of surgical treatment
Time of Update: 2021-10-20
The LRR pattern varies with the approach of the initial operation, and mainly involves chest wall recurrence after mastectomy, residual breast or regional lymph nodes (LNs) after BCS .
-
Blood: Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia
Time of Update: 2021-10-20
The purpose of this study is to use next-generation sequencing technology in long-term follow-up CIN patients (n=185) to study the frequency and clinical significance of gene mutations associated with myeloid malignancies .
-
The most comprehensive analysis in history!
Time of Update: 2021-10-20
This study aims to clarify the association between dietary intake and alpha linolenic acid (ALA) tissue biomarkers, as well as all-cause, cardiovascular disease (CVD) and cancer mortality risks .
-
Clinical Cancer Research: Human clinical trials show that cordycepin has outstanding anti-cancer effects after modification
Time of Update: 2021-10-20
The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase 1 clinical trial.
The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase 1 clinical trial.
-
Front Oncol: Preoperative chemotherapy combined with immunotherapy is safe and feasible for patients with resectable NSCLC
Time of Update: 2021-10-20
Patients who were 18 years of age or older, diagnosed with stage Ib-IIIb NSCLC and received neoadjuvant chemotherapy + immunotherapy and then undergoing surgery .
Adverse eventsAdverse eventsIn summary, studies have shown that preoperative chemotherapy combined with immunotherapy in patients with resectable NSCLC is safe and feasible .
-
The future of gene editing has been questioned. Due to serious safety issues, the FDA has suspended CAR-T clinical trials based on gene editing!
Time of Update: 2021-10-20
Because chromosomal abnormalities may lead to cancer, considering this serious potential risk, the FDA has suspended all CAR-T clinical trials of Allogene .
Because chromosomal abnormalities may lead to cancer, considering this serious potential risk, FDA FDA suspended all CAR-T clinical trials of Allogene .
-
The accuracy of blood test for the three major cancers is higher than 90%!
Time of Update: 2021-10-20
For training and validation sets and different amounts of lipids (138, 91, 29, and 7 lipids), the specificity ranges from 97% to 67 with an average of 83%, and the renal cancer sensitivity is an average of 49-74% 61%; the sensitivity of prostate cancer ranges from 0 to 66%, with an average of 43%, and the accuracy ranges from 57 to 74%, with an average of 65%, to construct an MDA model of male samples (Figure 8A) .
-
Front Oncol: Long-term survival outcome of gastric MALT lymphoma: results from a multicenter study in South Korea
Time of Update: 2021-10-20
In addition, the survival rate of patients with gastric MALT lymphoma was evaluated based on the stage and Helicobacter pylori infection .
In addition, the survival rate of patients with gastric MALT lymphoma was evaluated according to the stage and Helicobacter pylori infection .
-
The Scottish Medicines Federation (SMC) approves the combination of Cabometyx/Opdivo for the treatment of patients with advanced kidney cancer
Time of Update: 2021-10-20
1 months , Cabometyx combined with Opdivo reduced the risk of death in patients with advanced RCC by 34% compared with the currently available sunitinib therapy .
-
Image differential diagnosis of common tumors in sellar area
Time of Update: 2021-10-19
Male, 2 years old, with double vision impairmentA round cystic mass with long T1 and long T2 signals was seen in the sellar area, and the thickness of the cyst wall was uneven .
-
BREAST CANCER RES TR: Can low-risk early breast cancer be treated without chemotherapy after surgery?
Time of Update: 2021-10-19
Therefore, the results of this big data review study show that for patients with HER2-positive early breast cancer with tumors ≤ 2 cm and negative lymph nodes, although trastuzumab combined with chemotherapy is compared with trastuzumab monotherapy, 5 years The overall survival rate is 3.
-
Front Oncol: The effect of chemotherapy on the prognosis of patients with stage I nasopharyngeal carcinoma
Time of Update: 2021-10-19
Prognostic factors after PSM Prognostic factors after PSMIn summary, studies have shown that adding chemotherapy to radiotherapy does not improve the prognosis of patients with stage I nasopharyngeal carcinoma .
-
Is the new "cancer king" saved?
Time of Update: 2021-10-19
In this study, the researchers found in preclinical tests conducted in animal models that Bexarotene changed the state of TNBC cells from mesenchymal to epithelial, making TNBC cells more susceptible to conventional chemotherapy, which resulted in a longer-lasting response and thus Prevent recurrence of cancer .
-
The bispecific antibody achieves another success, halving the risk of death from metastatic uveal melanoma
Time of Update: 2021-10-11
On September 23, 2021, the New England Journal of Medicine (NEJM) published a phase 3 clinical trial of a new immunotherapy drug tebentafusp for the treatment of metastatic uveal melanoma.
-
Express significantly prolongs the lives of Asian liver cancer patients, and Keytruda reaches the phase 3 primary clinical endpoint
Time of Update: 2021-10-11
(MSD) announced that in Asian patients with advanced hepatocellular carcinoma (HCC) who have received sorafenib (sorafenib), the heavyweight PD-1 antibody A phase 3 clinical trial of the therapy Keytruda reached the primary endpoint of overall survival (OS) .
-
"The Lancet" Sub-Journal: In 82 countries' survey of oncologists, what are the "high-priority" basic anticancer drugs?
Time of Update: 2021-10-11
Oncologists’ "High Priority" Basic Anticancer Drugs According to the survey and analysis results, overall, the top 20 "high priority" anticancer drugs selected by 948 oncologists from 82 different countries around the world are as follows: Doxorubicin, Cisplatin, Paclitaxel, Pembrolizumab, Trastuzumab, Carboplatin, Fluorouracil, Tamoxifen, Capecitabine, Cyclophosphamide, Docetaxel, Oxaliplatin , Dexamethasone, nivolumab, rituximab, imatinib, gemcitabine, etoposide, osimertinib and letrozole .
-
2021 CSCO Innovation Prospects Prof. Wei Zhang Analyzes the "Breakthrough" of Otuzumab in the Treatment of Indolent Lymphoma
Time of Update: 2021-10-11
During the conference, Yimaitong was fortunate to invite Professor Zhang Wei from Peking Union Medical College Hospital to accept an interview to share clinical experience and talk about the changes that Otuzumab has brought to the treatment strategy of indolent B-cell lymphoma .
-
One person has colon cancer, the whole family must be screened!
Time of Update: 2021-10-11
The recent study published in The Lancet Oncology used 5585 LS families from 22 countries (including at least 3 members and a confirmed DNA mismatch repair gene or a family with a pathogenic carrier) to determine the risk of colorectal cancer.
